We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
Read MoreHide Full Article
Key Takeaways
Sotyktu sustained strong PsA responses through week 104, including ACR20/50/70 and MDA measures.
Bristol Myers reported no new safety signals for two years, supporting Sotyktu's longer-term use.
Sotyktu sales rose 24% year over year to $156 million in the first half of 2026.
Bristol Myers (BMY - Free Report) recently announced positive two-year results from the late-stage POETYK PsA-2 study on Sotyktu (deucravacitinib), including its open-label extension (OLE).
The two-year data provide additional support for Sotyktu’s commercial opportunity in psoriatic arthritis (PsA), particularly by demonstrating sustained efficacy and a consistent safety profile with longer-term treatment.
Among patients who entered the OLE, Sotyktu demonstrated durable efficacy, with clinical responses improving from week 16 through week 52 and sustained through week 104.
Responses remained robust across key efficacy measures, including ACR20/50/70 and Minimal Disease Activity (“MDA”), in both patients who received Sotyktu continuously from the start of the phase III study and those who switched from placebo to Sotyktu at week 16 and continued treatment through the OLE.
The safety profile also remained consistent through week 104, with no new safety signals identified. Adverse events occurred in 86.6% of 604 patients exposed to Sotyktu, while serious adverse events and discontinuations due to adverse events were reported in 12.6% and 7.6% of patients, respectively.
Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor. The drug is approved in the United States and numerous countries around the world for the treatment of adults with moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Sotyktu’s PsA approval earlier this year broadens its addressable market and provides another potential growth driver for
BMY’s Growth Portfolio.
Sotyktu generated $156 million of revenues in the first half of 2026, up 24% year over year.
The data is particularly relevant to BMY’s growth strategy as the company seeks to expand Sotyktu beyond psoriasis into additional immunology indications.
Additional upside could come from ongoing phase III programs in systemic lupus erythematosus and Sjögren’s disease, which may further broaden the drug’s addressable market, if successful.
Data from POETYK SLE-1 & 2 is expected later in 2026.
The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy — is becoming central to top-line resilience. Within this mix, Reblozyl, Breyanzi, Opdualag, Opdivo Qvantig, Camzyos and Cobenfy propelled growth in the first half.
Competition for BMY’s Sotyktu
Sotyktu faces stiff competition from Amgen’s (AMGN - Free Report) Otezla in the psoriasis space.
Amgen acquired global commercial rights to Otezla from erstwhile Celgene (now part of Bristol-Myers). Amgen is also evaluating Otezla in additional indications.
Takeda (TAK - Free Report) is evaluating zasocitinib for the treatment of adults with moderate-to-severe plaque psoriasis. The candidate is an investigational, next-generation, highly selective and potent oral TYK2 inhibitor. The FDA recently accepted TAK’s new drug application seeking approval of zasocitinib for the treatment of adults with moderate-to-severe plaque psoriasis.
Takeda is currently evaluating the safety and efficacy of zasocitinib in phase III studies in psoriatic arthritis and phase II studies in Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa.
BMY’s Price Performance, Valuation, Estimates and Zacks Rank
Shares of BMY have gained 16.5% year to date compared with the industry’s growth of 5.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, the stock currently trades at 9.58x forward earnings, higher than its mean of 8.70x but lower than the large-cap pharma industry’s 18.01x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.91 from $6.34 in the past 60 days, while that for 2027 has increased to $6.46 from $6.12.
View the Zacks #1 Rank List
Image: Shutterstock
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
Key Takeaways
Bristol Myers (BMY - Free Report) recently announced positive two-year results from the late-stage POETYK PsA-2 study on Sotyktu (deucravacitinib), including its open-label extension (OLE).
The two-year data provide additional support for Sotyktu’s commercial opportunity in psoriatic arthritis (PsA), particularly by demonstrating sustained efficacy and a consistent safety profile with longer-term treatment.
Among patients who entered the OLE, Sotyktu demonstrated durable efficacy, with clinical responses improving from week 16 through week 52 and sustained through week 104.
Responses remained robust across key efficacy measures, including ACR20/50/70 and Minimal Disease Activity (“MDA”), in both patients who received Sotyktu continuously from the start of the phase III study and those who switched from placebo to Sotyktu at week 16 and continued treatment through the OLE.
The safety profile also remained consistent through week 104, with no new safety signals identified. Adverse events occurred in 86.6% of 604 patients exposed to Sotyktu, while serious adverse events and discontinuations due to adverse events were reported in 12.6% and 7.6% of patients, respectively.
Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor. The drug is approved in the United States and numerous countries around the world for the treatment of adults with moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Sotyktu’s PsA approval earlier this year broadens its addressable market and provides another potential growth driver for
BMY’s Growth Portfolio.
Sotyktu generated $156 million of revenues in the first half of 2026, up 24% year over year.
The data is particularly relevant to BMY’s growth strategy as the company seeks to expand Sotyktu beyond psoriasis into additional immunology indications.
Additional upside could come from ongoing phase III programs in systemic lupus erythematosus and Sjögren’s disease, which may further broaden the drug’s addressable market, if successful.
Data from POETYK SLE-1 & 2 is expected later in 2026.
The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy — is becoming central to top-line resilience. Within this mix, Reblozyl, Breyanzi, Opdualag, Opdivo Qvantig, Camzyos and Cobenfy propelled growth in the first half.
Competition for BMY’s Sotyktu
Sotyktu faces stiff competition from Amgen’s (AMGN - Free Report) Otezla in the psoriasis space.
Amgen acquired global commercial rights to Otezla from erstwhile Celgene (now part of Bristol-Myers). Amgen is also evaluating Otezla in additional indications.
Takeda (TAK - Free Report) is evaluating zasocitinib for the treatment of adults with moderate-to-severe plaque psoriasis. The candidate is an investigational, next-generation, highly selective and potent oral TYK2 inhibitor. The FDA recently accepted TAK’s new drug application seeking approval of zasocitinib for the treatment of adults with moderate-to-severe plaque psoriasis.
Takeda is currently evaluating the safety and efficacy of zasocitinib in phase III studies in psoriatic arthritis and phase II studies in Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa.
BMY’s Price Performance, Valuation, Estimates and Zacks Rank
Shares of BMY have gained 16.5% year to date compared with the industry’s growth of 5.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, the stock currently trades at 9.58x forward earnings, higher than its mean of 8.70x but lower than the large-cap pharma industry’s 18.01x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.91 from $6.34 in the past 60 days, while that for 2027 has increased to $6.46 from $6.12.
Image Source: Zacks Investment Research
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.